Cellex Expands Facilities and Achievements in Cell and Gene Therapy Manufacturing

Cellex's Remarkable Journey in Cell and Gene Therapy

Cellex Cell Professionals, a prominent full-service Contract Development and Manufacturing Organization (CDMO) based in Germany, celebrates over ten years of innovation and excellence in the cell and gene therapy (CGT) manufacturing space. Founded in 2001 by Prof. Dr. Gerhard Ehninger, the organization has continuously evolved, prioritizing patient access and operational excellence.

Expansion and Achievement

In 2025, Cellex marked significant facility expansions and milestones within the CGT landscape. Over the years, the company has successfully established itself as a trusted partner in the manufacturing of advanced therapy medicinal products (ATMP). Recently, they have produced over 5,800 CGT batches, which includes more than 1,300 clinical and 4,500 commercial products.

Key Milestones

1. Facilities Growth: With major expansions in 2019 and subsequent years, Cellex has developed a GMP-certified manufacturing area exceeding 2,500 m². This area includes high-throughput cleanroom environments designed to enable enhanced productivity and quality.
2. Clinical and Commercial Support: The company currently manufactures various cellular intermediates and final drug products, including three CAR-T therapies approved for use in the European market. Notably, in 2023, it achieved the milestone of manufacturing Europe’s first allogeneic CAR-T product, reinforcing its role at the forefront of innovative therapy development.
3. Infrastructure for Quality: A new warehouse facility was initiated to improve the overall quality, safety, and efficiency of each batch produced, ensuring that they can meet the growing demand in CGT manufacturing.

Strategic Partnerships and Future Outlook

Cellex's partnerships with leading pharmaceutical companies reveal its credibility within the industry. They began collaboration with its first pharma client in 2017, followed by ongoing developments that promise further commercial deliveries in the near future.

In 2025, Cellex onboarded two additional clients, and their robust pipeline of mandates points toward a promising future, as they continue to serve clients from preclinical stages to commercial launch. Their commitment to precision and reliability plays a critical role in their approach, signaling their readiness to address evolving market demands.

Conclusion

Cellex Cell Professionals stands uniquely poised among European CDMOs. With over a decade of experience complemented by a proven track record in both autologous and allogeneic cell therapy manufacturing, Cellex is a critical player in the growth of cell and gene therapy. The company’s strategic expansions and partnerships not only enrich their capabilities but also contribute significantly to the broader landscape of healthcare solutions in the realm of cellular therapies.

For more information about Cellex and their services, visit their website.